Diagnostic and prognostic markers for human prostate cancer

Xiang Gao, Arthur T. Porter, David Grignon, J. Edson Pontes, Kenneth V. Honn

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

BACKGROUND. The incidence and mortality of prostate cancer are increasing at alarming rates, partially due to an aging population. Early detection of prostate cancer, using clinically sensitive procedures and/or tumor markers (e.g., prostate-specific antigen [PSA]), is of prime importance. However, the choice of therapeutic interventions for prostate cancer at the time of diagnosis is largely dependent on clinical and pathologic staging and prediction of the degree of aggressiveness of the disease. Clinically applicable prognostic markers are urgently needed to assist in the selection of optimal therapy. METHODS. Literature review of the potential diagnostic and prognostic markers for human prostate cancer. RESULTS. Well-established tissue prognostic indicators, including histologic grade, margin positivity, pathologic stage, intraglandular tumor extent, and DNA ploidy, are not reviewed in this paper. Recently, a number of novel markers have been identified. In this paper, we begin with a discussion of a number of well-established as well as investigational diagnostic markers and then focus on evaluation of prognostic markers. Diagnostic markers that have prognostic value and investigational prognostic markers are also discussed. CONCLUSIONS. Currently, only PSA is utilized for early diagnosis and monitoring of prostate cancer. A number of potential prognostic markers warrant further investigation. Multimarker analysis is implicated.

Original languageEnglish (US)
Pages (from-to)264-281
Number of pages18
JournalProstate
Volume31
Issue number4
DOIs
StatePublished - Jun 1 1997
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Prostate-Specific Antigen
Ploidies
Tumor Biomarkers
Early Detection of Cancer
Early Diagnosis
Mortality
DNA
Incidence
Therapeutics
Population
Neoplasms

Keywords

  • Diagnosis
  • Prognosis
  • Prostatic carcinoma
  • Tumor markers

ASJC Scopus subject areas

  • Urology

Cite this

Diagnostic and prognostic markers for human prostate cancer. / Gao, Xiang; Porter, Arthur T.; Grignon, David; Pontes, J. Edson; Honn, Kenneth V.

In: Prostate, Vol. 31, No. 4, 01.06.1997, p. 264-281.

Research output: Contribution to journalArticle

Gao, Xiang ; Porter, Arthur T. ; Grignon, David ; Pontes, J. Edson ; Honn, Kenneth V. / Diagnostic and prognostic markers for human prostate cancer. In: Prostate. 1997 ; Vol. 31, No. 4. pp. 264-281.
@article{bd903c78a0664e46835fc3c95169f638,
title = "Diagnostic and prognostic markers for human prostate cancer",
abstract = "BACKGROUND. The incidence and mortality of prostate cancer are increasing at alarming rates, partially due to an aging population. Early detection of prostate cancer, using clinically sensitive procedures and/or tumor markers (e.g., prostate-specific antigen [PSA]), is of prime importance. However, the choice of therapeutic interventions for prostate cancer at the time of diagnosis is largely dependent on clinical and pathologic staging and prediction of the degree of aggressiveness of the disease. Clinically applicable prognostic markers are urgently needed to assist in the selection of optimal therapy. METHODS. Literature review of the potential diagnostic and prognostic markers for human prostate cancer. RESULTS. Well-established tissue prognostic indicators, including histologic grade, margin positivity, pathologic stage, intraglandular tumor extent, and DNA ploidy, are not reviewed in this paper. Recently, a number of novel markers have been identified. In this paper, we begin with a discussion of a number of well-established as well as investigational diagnostic markers and then focus on evaluation of prognostic markers. Diagnostic markers that have prognostic value and investigational prognostic markers are also discussed. CONCLUSIONS. Currently, only PSA is utilized for early diagnosis and monitoring of prostate cancer. A number of potential prognostic markers warrant further investigation. Multimarker analysis is implicated.",
keywords = "Diagnosis, Prognosis, Prostatic carcinoma, Tumor markers",
author = "Xiang Gao and Porter, {Arthur T.} and David Grignon and Pontes, {J. Edson} and Honn, {Kenneth V.}",
year = "1997",
month = "6",
day = "1",
doi = "10.1002/(SICI)1097-0045(19970601)31:4<264::AID-PROS8>3.0.CO;2-K",
language = "English (US)",
volume = "31",
pages = "264--281",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Diagnostic and prognostic markers for human prostate cancer

AU - Gao, Xiang

AU - Porter, Arthur T.

AU - Grignon, David

AU - Pontes, J. Edson

AU - Honn, Kenneth V.

PY - 1997/6/1

Y1 - 1997/6/1

N2 - BACKGROUND. The incidence and mortality of prostate cancer are increasing at alarming rates, partially due to an aging population. Early detection of prostate cancer, using clinically sensitive procedures and/or tumor markers (e.g., prostate-specific antigen [PSA]), is of prime importance. However, the choice of therapeutic interventions for prostate cancer at the time of diagnosis is largely dependent on clinical and pathologic staging and prediction of the degree of aggressiveness of the disease. Clinically applicable prognostic markers are urgently needed to assist in the selection of optimal therapy. METHODS. Literature review of the potential diagnostic and prognostic markers for human prostate cancer. RESULTS. Well-established tissue prognostic indicators, including histologic grade, margin positivity, pathologic stage, intraglandular tumor extent, and DNA ploidy, are not reviewed in this paper. Recently, a number of novel markers have been identified. In this paper, we begin with a discussion of a number of well-established as well as investigational diagnostic markers and then focus on evaluation of prognostic markers. Diagnostic markers that have prognostic value and investigational prognostic markers are also discussed. CONCLUSIONS. Currently, only PSA is utilized for early diagnosis and monitoring of prostate cancer. A number of potential prognostic markers warrant further investigation. Multimarker analysis is implicated.

AB - BACKGROUND. The incidence and mortality of prostate cancer are increasing at alarming rates, partially due to an aging population. Early detection of prostate cancer, using clinically sensitive procedures and/or tumor markers (e.g., prostate-specific antigen [PSA]), is of prime importance. However, the choice of therapeutic interventions for prostate cancer at the time of diagnosis is largely dependent on clinical and pathologic staging and prediction of the degree of aggressiveness of the disease. Clinically applicable prognostic markers are urgently needed to assist in the selection of optimal therapy. METHODS. Literature review of the potential diagnostic and prognostic markers for human prostate cancer. RESULTS. Well-established tissue prognostic indicators, including histologic grade, margin positivity, pathologic stage, intraglandular tumor extent, and DNA ploidy, are not reviewed in this paper. Recently, a number of novel markers have been identified. In this paper, we begin with a discussion of a number of well-established as well as investigational diagnostic markers and then focus on evaluation of prognostic markers. Diagnostic markers that have prognostic value and investigational prognostic markers are also discussed. CONCLUSIONS. Currently, only PSA is utilized for early diagnosis and monitoring of prostate cancer. A number of potential prognostic markers warrant further investigation. Multimarker analysis is implicated.

KW - Diagnosis

KW - Prognosis

KW - Prostatic carcinoma

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=0030981435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030981435&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0045(19970601)31:4<264::AID-PROS8>3.0.CO;2-K

DO - 10.1002/(SICI)1097-0045(19970601)31:4<264::AID-PROS8>3.0.CO;2-K

M3 - Article

VL - 31

SP - 264

EP - 281

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 4

ER -